{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=empagliflozin&page=4", "query": { "intervention": "empagliflozin", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 142, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=empagliflozin&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=empagliflozin&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:46:07.510Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT01975220", "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Empagliflozin/Metformin XR FDC", "type": "DRUG" }, { "name": "25 mg Empagliflozin/1000 mg Metformin XR, FDC", "type": "DRUG" }, { "name": "1 tablet Empagliflozin/2 tablets Metformin XR", "type": "DRUG" }, { "name": "1 tablet Empagliflozin/3 tablets Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2013-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-03-08", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975220" }, { "nct_id": "NCT03152552", "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus and Heart Failure" ], "interventions": [ { "name": "LIK066", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2017-07-25", "completion_date": "2018-06-06", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 21, "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Carmichael", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152552" }, { "nct_id": "NCT07053306", "title": "SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Empagliflozin 25 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2025-04-29", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07053306" }, { "nct_id": "NCT07175051", "title": "Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)", "Albuminuria" ], "interventions": [ { "name": "Empagliflozin (oral)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 20, "start_date": "2026-04-08", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07175051" }, { "nct_id": "NCT05972564", "title": "The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Obesity", "Metabolic Syndrome" ], "interventions": [ { "name": "Empagliflozin 25 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2023-09-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05972564" }, { "nct_id": "NCT05510115", "title": "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Kidney, Autosomal Dominant" ], "interventions": [ { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2022-11-18", "completion_date": "2026-08-01", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05510115" }, { "nct_id": "NCT03448406", "title": "This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2018-03-20", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 43, "location_summary": "Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448406" }, { "nct_id": "NCT06201000", "title": "Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Genetic Polymorphisms", "Heart Failure" ], "interventions": [ { "name": "SGLT2 inhibitors (Dapagliflozin and Empagliflozin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "October 6 University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 282, "start_date": "2023-12-27", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06201000" }, { "nct_id": "NCT02597049", "title": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 424, "start_date": "2015-11", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2020-06-17", "last_synced_at": "2026-10-07T14:46:07.510Z", "location_count": 13, "location_summary": "Encino, California • Huntington Park, California • Los Angeles, California + 9 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597049" } ] }